Literature DB >> 27262909

The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy.

Hiroki Sato1, Shinichi Toyooka2, Junichi Soh1, Katsuyuki Hotta3, Kuniaki Katsui4, Hiromasa Yamamoto1, Seiichiro Sugimoto1, Takahiro Oto1, Susumu Kanazawa4, Katsuyuki Kiura3, Shinichiro Miyoshi1.   

Abstract

BACKGROUND: This study aimed to compare the morbidity and mortality of a median sternotomy approach and a lateral thoracotomy and to investigate the feasibility of a median sternotomy for locally advanced non-small cell lung cancer (NSCLC) after induction chemoradiotherapy.
METHODS: The medical records of patients with locally advanced NSCLC who underwent induction chemoradiotherapy followed by surgery at our institution between January 1999 and September 2014 were reviewed. We compared the morbidity and mortality of a median sternotomy approach and a lateral thoracotomy.
RESULTS: A total of 102 NSCLC patients were the subjects of this study. Among them, 31 patients underwent surgery with a median sternotomy approach and 71 patients underwent surgery with a lateral thoracotomy. Patients in the median sternotomy group had a significantly higher rate of postoperative arrhythmia than those in the lateral thoracotomy group (p = 0.0028). However, all the complications were manageable, and no treatment-related deaths occurred in the median sternotomy group. Regarding the prognosis, the 5-year overall survival rate was 72.7%, and the 2-year recurrence-free survival rate was 66.5% in the entire population. No significant differences in overall survival or recurrence-free survival were observed between the 2 approaches.
CONCLUSIONS: Whereas the lateral thoracotomy approach is a standard procedure, our experience suggests that a median sternotomy approach for locally advanced NSCLC after induction chemoradiotherapy is a feasible procedure and can be a surgical option.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27262909     DOI: 10.1016/j.athoracsur.2016.03.092

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy.

Authors:  Ken Suzawa; Junichi Soh; Yuta Takahashi; Hiroki Sato; Kazuhiko Shien; Hiromasa Yamamoto; Susumu Kanazawa; Katsuyuki Kiura; Shinichiro Miyoshi; Shinichi Toyooka
Journal:  Surg Today       Date:  2019-02-08       Impact factor: 2.549

2.  Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer.

Authors:  Kuniaki Katsui; Takeshi Ogata; Kenta Watanabe; Kotaro Yoshio; Masahiro Kuroda; Masaomi Yamane; Takao Hiraki; Katsuyuki Kiura; Shinichi Toyooka; Susumu Kanazawa
Journal:  Int J Clin Oncol       Date:  2021-04-20       Impact factor: 3.402

3.  Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?

Authors:  Hiroki Sato; Junichi Soh; Katsuyuki Hotta; Kuniaki Katsui; Susumu Kanazawa; Katsuyuki Kiura; Shinichi Toyooka
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-04-20       Impact factor: 1.520

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.